PMID: 12777270Jun 5, 2003Paper

Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men

The American Journal of Psychiatry
Mary Ann RichardsonLeslie Citrome

Abstract

The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested. Public-sector psychiatric patients with long histories of antipsychotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive branched-chain amino acids or placebo. Treatment frequency was three times a day, 7 days a week for 3 weeks. The efficacy measure was a frequency count of videotaped tardive dyskinesia movements. A robust and highly significant difference was observed between patients who received high-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of the 3-week trial. Significant and marked differences were seen between the two groups at the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms. No clinically significant differences were seen between the pre- and posttrial results of physical examinations and laboratory screening tests. Minimal gastrointestinal symptoms occurred during the trial. The reduction in tardive dyskinesia symptoms in the amino acids group was not related to changes in antip...Continue Reading

Citations

Dec 1, 2005·International Clinical Psychopharmacology·Jonas EberhardSten Levander
Feb 16, 2006·The Australian and New Zealand Journal of Psychiatry·Janna S Gordon-Elliott, Howard C Margolese
Nov 16, 2013·Drug Design, Development and Therapy·Abdul Qayyum RanaPierre J Blanchet
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Leslie J CloudStewart A Factor
Feb 16, 2005·Expert Opinion on Drug Safety·Robert L Rodnitzky
Jun 15, 2011·Journal of Psychosocial Nursing and Mental Health Services·Robert H Howland
Oct 22, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Vivian KafantarisNatasha Bennett
Jan 6, 2015·Psychiatry and Clinical Neurosciences·Paul P LernerVladimir Lerner
Apr 27, 2017·Expert Opinion on Pharmacotherapy·Daniel P WitterUma Suryadevara
Jan 7, 2017·The Journal of Head Trauma Rehabilitation·Bhanu SharmaMichael G Hutchison
Jan 13, 2006·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Mary Ann RichardsonRaymond F Suckow
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Dec 9, 2004·Current Opinion in Clinical Nutrition and Metabolic Care·Giampaolo BianchiGiulio Marchesini
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable
Mar 20, 2018·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserHanna Bergman
Sep 2, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jason M Noel, Cherry W Jackson
Jun 3, 2005·The Journal of Nutrition·John D Fernstrom

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Journal of Clinical Psychiatry
Mary Ann RichardsonJames D Clelland
International Review of Psychiatry
Krishna VaddadiJohn Waddington
Progress in Neuro-psychopharmacology & Biological Psychiatry
Christina W SlotemaHans W Hoek
© 2022 Meta ULC. All rights reserved